ThursdayMay 25, 2017 1:49 pm

Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) to Step Up Exploration Efforts following Chinese Production Cuts

Zinc prices soared over the last few days after top consumer China increased imports of the metal in wake of the country’s halting production as part of an environmental crackdown on the local steel industry. The Asian nation’s move to curb zinc and nickel production is likely to have a significant impact on global supply, with inventories already under pressure from growing demand and currently at about 342,675 tons (roughly 20 percent lower than last year), according to Reuters (http://nnw.fm/DfJX0). Zinc exploration corporations such as Vancouver-based Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) are already exploring ways to step up…

Continue Reading

ThursdayMay 25, 2017 9:16 am

More Mobile Usage Means More Mobile Payments for Net Element (NASDAQ: NETE)

The global mobile revolution continues to accelerate.  It’s estimated that, currently, about 4.8 billion individuals globally use a mobile phone, with about 2.3 billion of them being smart phone users. Smartphone subscribers now represent over half of the global mobile population. Mobile devices are fast becoming the go-to technology, even in mature economies where people can use alternative devices at home. Expanded mobile usage even engenders and propagates new behavior sets among consumers. More mobile usage even drives the usage of mobile devices to make purchases. Approximately $37 billion in mobile transactions occurred in 2015, and that total is expected to explode to over…

Continue Reading

WednesdayMay 24, 2017 3:01 pm

India Globalization Capital, Inc. (NYSE: IGC) Taps Dr. Craig Cheifetz as Advisor for Clinical Trials of Cannabis-Based Combination Therapies

India Globalization Capital, Inc. (NYSE MKT: IGC) has named Craig Cheifetz, M.D., as an advisor to aid the company in its clinical trials in microbiology, immunology, neuroscience, and biotechnology. IGC is engaged in the development of cannabis-based therapies, which treat pain, terminal neurological and oncological diagnosis, PTSD, seizures, and other life altering issues. The company, based in Bethesda, Maryland, has a portfolio of patent filings for its phytocannabinoid-based treatments. In a news release, Ram Mukunda, CEO of IGC, welcomed Cheifetz to the company's advisory team, noting that he looks forward to Chiefetz's contributions as IGC develops unique cannabis combination therapies.…

Continue Reading

WednesdayMay 24, 2017 12:25 pm

Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) Aims for Strike at Sully Project Amid Global Zinc Shortage

It is a prime time to be in the zinc mining business, and Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) is poised to profit in the midst of a continuing global zinc shortage and simultaneously booming prices. As recently reported (http://nnw.fm/3lzC3), the price of zinc rose to $1.17 per pound and $2,628 per metric ton as of May 2017, representing a 60 percent increase over the previous year’s prices. This exceeded already propitious predictions that a deeper worldwide shortage would send zinc prices soaring as high as $2,500 per metric ton over the course of 2017 (http://nnw.fm/QXe2r). The current imbalance…

Continue Reading

WednesdayMay 24, 2017 11:24 am

BioCorRx, Inc. (BICX) Targeting Alcohol and Opioid Addiction with Innovative Two-Pronged Approach

BioCorRx (OTCQB: BICX) is the owner and creator of an innovative addiction treatment program used by a network of independent treatment centers to improve the lives of their patients struggling with alcohol and opioid addictions. The BioCorRx® Recovery Program leverages an innovative, two-pronged approach that addresses the underlying physical and behavioral issues associated with these addictions. The first half of this approach relies on a highly effective, proprietary implant formulation of the FDA-approved medication naltrexone, for which BioCorRx holds worldwide license rights (excluding Australia and New Zealand). The second half focuses on a modular counseling program coupled with overlapping peer…

Continue Reading

WednesdayMay 24, 2017 9:00 am

Evolution of Marijuana Industry Creates Wealth of Opportunity for Companies with Foresight and Action

NetworkNewsWire Editorial Coverage: The marijuana industry continues to evolve at a breakneck pace in the United States, and an increasing number of businesses are finding their niche in this rampant market as it burns toward nationwide legalization. In the wake of this evolution, various new types of businesses are emerging to provide the consumer and commercial markets with products and services such as branding and packaging, smoke lounges, cultivation operations, grow equipment, pain management, payment solutions and numerous others. SinglePoint, Inc. (SING) (SING Profile), Medical Marijuana, Inc. (MJNA), Kush Bottles, Inc. (KSHB), Scott’s Miracle-Gro Co. (SMG) and Canopy Growth Corp.…

Continue Reading

TuesdayMay 23, 2017 1:08 pm

ChineseInvestors.com (CIIX) Growing Rapidly in a Rapidly Growing Market

Savvy investors study multiple factors to identify potential stock winners. Stock screeners scan thousands of companies for insights and data to discern uncommon opportunities. The criteria utilized in a stock screening system is obviously influenced by an individual’s investment proclivities such as high yield, value, growth or price momentum, however, most stock screening systems are typically hybrids with blended criteria reflecting individual preferences and incorporating more than one investment style. P/E ratios, near zero beta, increased dividends, revenue growth and market growth are all employed to sift through over 100,000 public companies around the world and the nearly 6,000 U.S.…

Continue Reading

TuesdayMay 23, 2017 11:40 am

Moxian, Inc. (NASDAQ: MOXC) Solidifies its Financials as it Competes in China’s Growing O2O Marketplace

Moxian, Inc. (NASDAQ: MOXC) has solidified its financial position as it competes in the massive Chinese sector of online-to-offline marketing. SeeThruEquity (http://nnw.fm/qTeF0) projected that the company could attain revenues of $24.1 million and net income of $4.5 million in FY 2018 as the O2O market is estimated to reach $48 billion in 1H17, according to investor materials provided by Moxian.  One caveat to SeeThruEquity’s projections was for Moxian to demonstrate its ability to raise additional capital to finance its ambitious plans to compete in such a large market. The high technology Shenzhen, China-based company netted some $8.5 million in an…

Continue Reading

TuesdayMay 23, 2017 9:34 am

Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) Looks at Lustrous Future as Zinc Futures Climb

The future of the Kootenay Zinc Corporation (CSE: ZNK) (OTCQB: KTNNF) has turned as lustrous as the metal it is mining. As zinc futures continue to climb, the company is intensifying its exploration activities at the Sully Project, located close to the shuttered Sullivan Mine, one of the world’s largest SEDEX deposits ever discovered. There are increasing indications from ground magnetic and gravity (MAG) data that ‘there is a magnetic component to the gravity masses’ surveyed, the company recently reported. Zinc, although not itself magnetic, has the peculiar property of being repelled by a magnetic field. Now, Kootenay Zinc Corporation…

Continue Reading

MondayMay 22, 2017 9:19 am

India Globalization Capital, Inc. (NYSE: IGC) Developing Phytocannabinoid-Based Product Pipeline to Treat Two- and Four-Legged Alike

Looking to gain an advantageous foothold in the burgeoning medical marijuana market, India Globalization Capital, Inc. (NYSE MKT: IGC) is developing innovative cannabis-based combination therapies that have application for both humans and animals. The company’s focus is on treating pain, post-traumatic stress disorder (PTSD), chronic and terminal neurological and oncological diagnoses, cachexia, and other life-altering medical conditions. IGC continues developing a portfolio of patent filings for phytocannabinoid-based treatments and has filed six patents to date. The company currently has three products in pre-clinical trials: IGC-501 for treatment of neuropathic pain in adult humans, IGC-502 for treatment of seizures in animals,…

Continue Reading

Contact us: 212.418.1217